Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Av-101. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Av-101 SCHEMBL18742668 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL30852264 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL30216614 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL5286788 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL30733184 | 1.00 | KMO (0.51) | KMOHIF1AKDM4ETDP1ABL1 | |
| Av-101 SCHEMBL16098317 | 0.93 | KMO (0.46) | KMOHIF1AKDM4ETDP1ABL1 | |
| SCHEMBL8397345 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 | |
| SCHEMBL30852448 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 | |
| SCHEMBL8397341 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 | |
| SCHEMBL30852441 | 0.88 | KMO (0.51) | KMOHIF1AKDM4ETDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | SOLIOME INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4587007-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | Soliome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250161251-A1 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | VISTAGEN THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | US | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| EP-2970080-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | Vistagen Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| US-20150359772-A1 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE | VISTAGEN THERAPEUTICS, INC. | 2015-12-17 | — | — | US | claimed |
| EP-2948140-A1 | DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE | Vistagen Therapeutics, Inc. (US) | 2015-12-02 | — | — | EP | claimed |
| US-20140309311-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2014-10-16 | — | — | US | claimed |
| WO-2014152835-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| WO-2014116739-A1 | DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE | VISTAGEN THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | claimed |
| EP-2582366-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2013-04-24 | — | — | EP | claimed |
| WO-2011157391-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PAIN | Grünenthal GmbH (DE) | 2011-12-22 | — | — | WO | claimed |
| US-20110306674-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2011-12-15 | — | — | US | claimed |
| US-20080287774-A1 | Magnetic Resonance Imaging and Spectroscopy Means and Methods Thereof | BRAIN WATCH LTD. (IL) | 2008-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KMO 2000/4885HIF1A 3441/4885KDM4E 4740/4885 |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KMO 2000/4885HIF1A 3441/4885KDM4E 4740/4885 |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KMO 2000/4885HIF1A 3441/4885KDM4E 4740/4885 |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KMO 2000/4885HIF1A 3441/4885KDM4E 4740/4885 |
| US-20110306674-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | KMO 157/4885HIF1A 1562/4885KDM4E 1665/4885 |
| US-20140309311-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | KMO 157/4885HIF1A 1562/4885KDM4E 1665/4885 |
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | UGT8, UGT1A3, FUT5 | KMO 2997/4885HIF1A 3431/4885KDM4E 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.